Under the terms of her contract described in Securities and Exchange Commission filings, Ms. Bresch is eligible to get severance equal to three times her $1.3 million base salary and the highest bonus she has ever received. This amounts to $18.6 million in cash. Additionally, she will pick up vested benefits, which are estimated at $19 million.
Ms. Bresch’s decision to leave the company was made public July 29 as part of the announcement that Mylan would merge with Pfizer’s Upjohn unit to create a generic medication powerhouse.
“After much reflection and nearly 28 years of service, I believe that this historic milestone in Mylan’s amazing journey is also the right time for me to retire from Mylan and pursue a new chapter in my career,” Ms. Bresch said in a news release from the company.
According to The Pittsburgh Post Gazette, Ms. Bresch and four other top executives may walk away from the deal with $93 million in compensation.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Clinics leaving family planning program may have to toss thousands of dollars worth of drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.